For patients with poor prognosis, acute lymphoblastic leukemia (ALL) allogeneic stem cell transplantation (SCT) is an option. Recently, the possibility to monitor responses of leukemia to first-line chemotherapy below the level of morphological detection by the sensitive analysis of minimal residual disease (MRD) in children has gained momentum. In principle, the detection of MRD in the case of ALL is based on the fact that the leukemic clone is derived from a progenitor cell in which the genes for the antigen receptors (B-or T-cell receptor (TCR)) have, at least partially, rearranged. These rearrangements are (almost) unique for each lymphocyte and can be regarded as a molecular 'fingerprint' for the leukemia. Specific detection of this fingerprint can therefore be used as a sensitive marker of the presence of leukemic cells, although in practice the polyclonal background of the normal lymphocytic cells can limit the sensitivity.
Measurement of MRD using real-time quantitative polymerase chain reaction (RQ-PCR) is or will be incorporated in most European first-line treatment protocols, so that patient stratification, according to conventional characteristics at the onset and response variables, such as prednisone response and achievement of remission after induction, is further improved by MRD levels measured at crucial points. 1 The rationale is that conventional treatment does not appropriately cure patients characterized by slow MRD clearance, and would require treatment intensification to be eventually cured. MRD levels have also been shown to be of importance in conjunction with SCT. As has been known since a number of years, pre-SCT levels of MRD can help to predict relapse probabilities after SCT. 2 Pediatric patients with relatively high levels of remaining leukemic cells in their bone marrow of 1 Â 10
À3 just prior to transplantation have a probability of relapse of about 80%, while patients with very low 1 Â 10 À5 or undetectable MRD have a relapse probability of only 25-30%. 3, 4 These initial results from retrospective analyses could be confirmed by an interim analysis of a large prospective multicenter trial performed in Germany (presented by P Bader). MRD analysis was performed using RQ-PCR analysis of TCR gene and immunoglobulin heavy-chain (IGH) gene rearrangements as reported previously. [5] [6] [7] [8] Until to date, 117 children transplanted for ALL were included. Transplants have been performed either in CR1 (n ¼ 39), CR2 (n ¼ 57) or CR42 (n ¼ 21). Patients who were transplanted while their MRD level was negative had a 3-year event-free survival (EFS) of 79%, patients with a low, but detectable MRD level below 1 Â 10 À3 had an EFS of 49% and children with a high MRD level (41 Â 10
À3
) of only 14%. These results were consistent with a smaller series of patients reported by A Balduzzi from Monza, Italy. MRD analysis resulted in positive results in eight and negative results in 10 of 18 ALL patients transplanted and monitored in a single transplant center. Three of the eight MRD-negative patients (38%) relapsed and three died of transplant-related mortality (TRM); among the 10 MRDpositive patients, six (60%) relapsed and one died of TRM. Of four MRD-positive patients who were in CR1, one relapsed, while five of the six MRD-positive patients who were in more advanced phases of disease relapsed. This would suggest a differential predictive role of MRD positivity pre-SCT according to the phase of the disease at transplantation, with a stronger impact of MRD positivity pre-SCT for patients in CR2 or CR3 than for patients in CR1. On the basis of the results of MRD analysis before SCT and its predictive value after SCT, it is highly recommended to perform MRD measurements before transplant with the aim to offer differential treatment protocols to patients with different relapse risks (see below).
In addition to the use of MRD levels prior to transplantation, MRD levels can also be monitored after SCT in order to predict an upcoming relapse, according to the kinetics of MRD levels. The impact of the detection of post transplant MRD levels on the prediction of relapse is not very straightforward. Positive MRD measurements during the first 6 months post-SCT occur not only in patients who relapse but also in patients who do not relapse. 9 In the German multicenter trial, it could be shown, however, that patients who developed MRD levels above 1 Â 10 À3 in their bone marrow at any time post transplant would ultimately relapse. A major obstacle of using post-SCT MRD levels as possible tools for the prevention of relapses is that relapses can occur soon after transplant and/or the interval between the increase in MRD level and overt relapse is often very short. To gain enough time for pre-emptive intervention based on results of post-SCT MRD analysis in bone marrow, sampling should be performed quite frequently and this is difficult to perform, particularly in children. Therefore, it will be very interesting to see whether MRD results in peripheral blood could also be helpful to predict upcoming relapse. It has been reported that for T-lineage ALL, which are of thymic origin, peripheral blood MRD values are comparable to the levels in bone marrow, while for B-lineage ALL, there are major discrepancies. 10 B ALL MRD levels in bone marrow are usually higher (sometimes up to 1000-fold) than in blood. However, for the purpose of measuring changes (ie increases) in MRD levels, peripheral blood measurements might still suffice. Preliminary results are encouraging, although final proof still has to be obtained.
A very different, but useful parameter in clinical management of post transplantation relapses in ALL patients is the kinetics of hematopoietic chimerism. It was reported that patients who do not achieve complete donor chimerism post transplant are more likely to develop subsequent relapse than patients who were complete chimeras already at day þ 30 (presented by M Ramirez from Madrid, Spain). Complete donor chimerism, on the other hand, was associated with higher TRM caused by, among others, a higher incidence of graft-versus-host disease (GVHD). When chimerism in patients is serially analyzed after SCT, it has been observed that changes in chimerism, that is, increasing contribution of the recipient's own hematopoietic system, are predictive of relapse. 11, 12 These increases in recipient cells do not necessarily have to be in the same lineage as the leukemic cells, but can be measured in total PBMC. Identification, either before or after transplant, of patients with a high risk of relapse after transplantation, using either (changes in) chimerism or MRD levels, is only useful if some kind of intervention is possible to increase the chance of survival of these patients. Treatment with additional chemotherapy after SCT may only have a limited effect on leukemic cells that have already experienced extensive first-line chemotherapy and the chemotherapy associated with the conditioning regimen, including irradiation. Only the use of different therapeutics with novel cellular targets might offer some options in this case. As well, toxicity may impose limitations on the use of any additional chemotherapy. Occasionally, second transplantations are being performed, but long-term success in these cases is limited. The most promising interventions that are commonly used are aiming to obtain an alloreactive graftversus-leukemia (GVL) effect. This effect is supposed to be mediated by alloreactive lymphocytes (T or NK) of donor origin with specificity for the recipient. The rationale behind this approach is that immunological graft-versushost reactivity may also exert a GVL effect, since the leukemia is of host origin. At this moment, the interventions used in this 'crude' form of immunotherapy consist mainly of tapering of immunosuppressive medication or infusion of donor lymphocytes (DLI). A potential hazard of this approach is that very severe GVHD may be induced that may not be controlled very easily and could potentially be life threatening. A potential development for the future may be the targeting of antigens on the leukemic cells that are not (or almost not) expressed on normal tissues of the patient. These antigens could be leukemia-specific antigens or minor transplantation antigens. Targeting minor transplantation antigens with an expression pattern that is restricted to the hematopoietic system may be a promising development to eradicate leukemia without the accompanying risk of GVHD. 13 Pre-emptive immunotherapy at this moment may follow two different approaches. Treatment can be based on (1) pre-SCT MRD levels or (2) post-SCT (changes in) chimerism and/or MRD levels. Both concepts are currently being explored in investigative studies. Bader et al reported a large prospective multicenter trial in Germany. Serial analysis of hematopoietic chimerism in peripheral blood cells can identify patients with an increased risk of relapse.
14 In a group of these high-risk children, relapse could be prevented by pre-emptive immunotherapy. However, not all children who relapsed could be identified in advance. Therefore, the use of a combination of both post-SCT chimerism and pre-SCT MRD levels is currently being studied. A second approach, based on pre-SCT MRD levels, was chosen in the Netherlands where a national protocol has been implemented for all children treated with allogeneic SCT for ALL. Patients are transplanted in one of the two national pediatric transplant centers in Utrecht and Leiden and MRD measurements are performed at the Erasmus Medical Center in Rotterdam. When a patient becomes eligible for transplantation, a target search is being initiated for suitable TCR/IgH rearrangements to be used as targets for MRD measurements. Of 26 patients included until now, suitable targets, that is, at least one target with a sensitivity of 1 Â 10 À3 , were identified in 22 patients. In 10 patients, two targets with a sensitivity of at least 1 Â 10 À4 , were identified. At 2 weeks before transplant, two bone marrow aspirates are taken and the level of MRD is determined. At the latest, the MRD level is known 4 weeks post-SCT. At that time, patients with more than one leukemic cell per 1 Â 10 4 cells in the bone marrow are being treated differently than patients with lower or undetectable levels of leukemic cells. The cutoff level of 1 Â 10 À4 has been chosen as an arbitrary threshold above which the chance of relapse is high enough to perform an 'immunotherapeutic' intervention aiming for a GVL effect through GVHD. In these patients, the cyclosporin A (CsA) is rapidly tapered (4 weeks post-SCT for non-T-cell-depleted transplantations and 5 weeks post-SCT for T-cell-depleted transplantations, excluding recipients of haploidentical grafts) and patients are observed for another 4 weeks after tapering for development of GVHD. When no GVHD grade II has been reached 4 weeks after tapering CsA, donor lymphocytes are infused at a dose of 1 Â 10 6 CD3 þ cells/kg in the case of non-T-cell-depleted transplantations and 5 Â 10 À4 CD3 þ cells/kg for T-celldepleted transplantations. If no GVHD grade II occurs within a period of 4-6 weeks, another DLI is given with two times more CD3 þ cells. Again, if no GVHD grade II develops, another DLI with twice as many T cells is given and this is continued until three to four DLI have been given.
In all, 17 patients have been transplanted and included in the protocol with a follow-up of 4-33 months. Of these 17 patients, 10 had pre-SCT MRD levels below 1 Â 10 À4 and were transplanted without further intervention, that is, CsA tapering at 3-6 months post-SCT. Of these 10 patients, five have relapsed until now, which is slightly higher than expected, although the number of patients included is still very low. Three patients developed GVHD (grades I and II), and two of those relapsed.
In seven patients, MRD levels were above 1 Â 10
À4
. Post transplant intervention was started in 6/7 patients (in 3/6 tapering of CsA only, in 3/6 tapering CsA þ DLI, one transplantation was syngeneic). GVHD grade II was achieved in 2/7 patients after tapering of CsA only and was controlled by treatment. Relapse occurred in 2/7 patients, and both cases had not developed GVHD. One of these two patients had just received the first DLI. The other two patients who received DLI received three incremental doses of CD3 þ cells without any signs of GVHD and remained relapse free. As no TRM was seen, these data indicate that early reduction of immunosuppression (4-5 weeks post-SCT) and low-dose DLI can be safely performed following SCT in children. Although the low relapse frequency in the MRD hi group of patients suggests a beneficial effect of the intervention, longer follow-up and inclusion of more patients is necessary to demonstrate whether this intervention protocol will have an impact on overall survival of children transplanted for ALL.
Concluding remark
The major cause of treatment failure after SCT is relapse, which has very poor prognosis. Whether early prediction of relapse will allow effective treatment is still to be assessed. Nevertheless, early identification of patients at risk is an important prerequisite in order to improve survival. Measurements of MRD and/or chimerism may play a crucial role to achieve this goal. However, once identified, alternative treatment protocols should also become available. At present, the best available tool for physicians consists of the rather nonspecific allogeneic GVL effect. In the future, more sophisticated and specific immunological antitumor approaches may be developed to increase the cure rate of allogeneic stem cell transplantation.
